Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Ruth, I. Mansson, N. Sandberg.
The prevalance of symptoms sugestive of esophageal disorders.
Scand J Gastroenterol, 26 (1991), pp. 73-81
[2.]
G.R. Locke, N.J. Talley.
Prevalance and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota.
Gastroenterology, 112 (1997), pp. 1.448-1.456
[3.]
V. Stanghellini.
Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol, 231 (1999), pp. 20-28
[4.]
S.J. Veldhuyzen van Zanten, N. Flook, N. Chiba, D. Armstrong, A. Barkun, M. Bradette, et al.
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori.
Canadian Dyspepsia Working Group. CMAJ, 162 (2000), pp. S3-S23
[5.]
P. Enck, D. Dubois, P. Marquis.
Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol, 231 (1999), pp. 48-54
[6.]
D.A. Revicki, M. Wood, P.N. Maton, S. Sorensen.
The impact of gastroesophageal reflux disease on health-related quality of life.
Am J Med, 104 (1998), pp. 252-258
[7.]
J. Dent, J. Brun, A.M. Fendrick, M.B. Fennerty, J. Janssens, P.J. Kahrilas, et al.
An evidence-based appraisal of reflux disease management-The Genval Workshop Report.
Gut, 44 (1999), pp. S1-S16
[8.]
S. Nandurkar, N.J. Talley.
Epidemiology and natural history of reflux disease.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 743-757
[9.]
Z. Younes, D.A. Johnson.
Diagnostic evaluation in gastroesophageal reflux disease.
Gastroenterol Clin North Am, 28 (1999), pp. 809-830
[10.]
M.A. Van Herwaarden, A.J. Smout.
Diagnosis of reflux disease.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 759-774
[11.]
C.A. Flynn.
The evaluation and treatment of adults with gastroesophageal reflux disease.
J Fam Pract, 50 (2001), pp. 57-63
[12.]
R.C. Heading.
Prevalence of gastrointestinal symptoms in the general population: a systematic review.
Scand J Gastroenterol, 231 (1999), pp. 3-8
[13.]
Anónimo.
Systematic review of PPI and H2A in GORD.
Bandolier, (1997),
[14.]
M. Savary, G. Miller.
The esophagus. Handbook and atlas of endoscopy.
pp. 135-142
[15.]
A. Meining, M. Classen.
The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease.
Am J Gastroenterol, 95 (2000), pp. 2.692-2.697
[16.]
S.J. Spechler.
Epidemiology and natural history of gastro-oesophageal reflux disease.
Digestion, 51 (1992), pp. 24-29
[17.]
L.A. Bradley, J.E. Richter, T.J. Pulliam, J.M. Haile, I.C. Scarinci, C.A. Schan, et al.
The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors.
Am J Gastroenterol, 88 (1993), pp. 11-19
[18.]
J. Lagergren, R. Bergstrom, O. Nyren.
No relation between body mass and gastroesophageal reflux symptoms in a Swedish population based study.
Gut, 47 (2000), pp. 26-29
[19.]
S. Vigneri, R. Termini, V. Savarino, F. Pace.
Review article: is Helicobacter pylori status relevant in the management of GORD?.
Aliment Pharmacol Ther, 14 (2000), pp. 31-42
[20.]
P. Malfertheiner, C. Gerards.
Helicobacter pylori infection and gastro-oesophageal reflux disease: coincidence or association.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 731-741
[21.]
R.H. Holloway.
The anti-reflux barrier and mechanisms of gastrooesophageal reflux.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 681-699
[22.]
D.S. Weinberg, S.L. Kadish.
The diagnosis and management of gastroesophageal reflux disease.
Med Clin North Am, 80 (1996), pp. 411-429
[23.]
Ontario Programe for optimal therapeutic.
Ontario Guideline for peptic ulcer disease and gastroesophageal reflux, (2000),
[24.]
A.G. Klauser, N.E. Schindlbeck, S.A. Muller-Lissner.
Symptoms in gastro-oesophageal reflux disease.
Lancet, 335 (1990), pp. 205-208
[25.]
R. Jones, S. Lydeard.
Prevalence of symptoms of dyspepsia in the community.
BMJ, 298 (1989), pp. 30-32
[26.]
R. Carlsson, J. Dent, E. Bolling-Sternevald, F. Johnsson, O. Junghard, K. Lauritsen, et al.
The usefulness of a structured questionnaire in the assesment of symptomatic gastroesophageal reflux disease.
Scand J Gastroenterol, 33 (1998), pp. 1.023-1.029
[27.]
N.J. Talley, V. Stanghellini, R.C. Heading, K.L. Kock, J.R. Malagelada, G.N.J. Tytgat.
Functional gastroduodenal disorders.
Gut, 45 (1999), pp. II37-II42
[28.]
K.R. DeVault, D.O. Castell.
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease The Practice Parameters Committee of American College of Gastroenterology.
Am J Gastroenterol, 94 (1999), pp. 1.434-1.442
[29.]
American Society For Gastrointestinal Endoscopy.
The role of endoscopy in the management of GERD: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy.
Gastrointest Endosc, 49 (1999), pp. 834-883
[30.]
L.R. Lundell, J. Dent, J. Bennett, A.L. Blum, D. Armstrong, J.P. Galmiche, et al.
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification.
Gut, 45 (1999), pp. 172-180
[31.]
F. Johnsson, L. Weywadt, J.N. Sonhaug, H. Hernqvist, L. Bengtsson.
One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease.
Scand J Gastroenterol, 33 (1998), pp. 15-20
[32.]
N.E. Schindlbeck, A.G. Klauser, W.A. Voderholzer, S.A. Muller-Lissner.
Empiric therapy for gastroesophageal reflux disease.
Arch Intern Med, 155 (1995), pp. 1.808-1.812
[33.]
T.M. Ours, M.S. Kavuru, R.J. Schilz, J.E. Richter.
A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough.
Am J Gastroenterol, 94 (1999), pp. 3.131-3.138
[34.]
H.B. El-Serag, P. Lee, A. Buchner, J.M. Inadomi, M. Gavin, D.M. McCarthy.
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Am J Gastroenterol, 96 (2001), pp. 979-983
[35.]
P.J. Kahrilas.
Strategies for medical management of reflux disease.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 775-791
[36.]
J.P. Waring, J.G. Hunter, M. Oddsdottir, J. Wo, E. Katz.
The preoperative evaluation of patients considered for laparoscopic antirefluxsurgery.
Am J Gastroenterol, 90 (1995), pp. 35-38
[37.]
P.J. Kahrilas, E.M. Quigley.
Clinical esophageal pH recording: a technical review for practice guideline development.
Gastroenterology, 110 (1996), pp. 1.982-1.996
[38.]
C. Winters Jr, T.J. Spurling, S.J. Chobanian, D.J. Curtis, R.L. Esposito, J.F. Hacker, et al.
Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease.
Gastroenterology, 92 (1987), pp. 118-124
[39.]
N.J. Shaheen, M.A. Crosby, E.M. Bozymski, R.S. Sandler.
Is there publication bias in the reporting of cancer risk in Barrett's esophagus?.
Gastroenterology, 119 (2000), pp. 333-338
[40.]
S.J. Spechler, R.K. Goyal.
Barrett's esophagus.
N Engl J Med, 315 (1986), pp. 362-371
[41.]
R.E. Sampliner.
Adenocarcinoma of the esophagus and gastric cardia: is there progress in the face of increasing cancer incidence?.
Ann Intern Med, 130 (1999), pp. 67-69
[42.]
J. Lagergren, R. Bergstrom, A. Lindgren, O. Nyren.
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.
N Engl J Med, 340 (1999), pp. 825-831
[43.]
W.H. Chow, W.D. Finkle, J.K. McLaughlin, H. Frankl, H.K. Ziel, J.F. Fraumeni Jr..
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.
JAMA, 274 (1995), pp. 474-477
[44.]
W.J. Blot, S.S. Devesa, R.W. Kneller, J.F. Fraumeni Jr..
Rising incidence of adenocarcinoma of the esophagus and gastric cardia.
JAMA, 265 (1991), pp. 1.287-1.289
[45.]
E.I. Heath, P.J. Limburg, E.T. Hawk, A.A. Forastiere.
Adenocarcinoma of the esophagus: risk factors and prevention.
Oncology (Huntingt), 14 (2000), pp. 507-514
[46.]
D.Y. Graham, D.J. Patterson.
Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis.
Dig Dis Sci, 28 (1983), pp. 559-563
[47.]
S. Chatfield.
Comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastrooesophageal reflux disease.
Curr Med Res Opin, 15 (1999), pp. 152-159
[48.]
L.S. Saco, R.C. Orlando, S.L. Levinson, E.M. Bozymski, J.D. Jones, J.T. Frakes.
Double-blind controlled trial of betanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis.
Gastroenterology, 82 (1982), pp. 1.369-1.373
[49.]
D. Earnest, M. Robinson, S. Rodriguez-Stanley, A.A. Ciociola, P. Jaffe, M.T. Silver, et al.
Managing heartburn at the “base” of the GERD “iceberg”: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids.
Aliment Pharmacol Ther, 14 (2000), pp. 911-918
[50.]
Clinical Evidence, (2001),
[51.]
B. Van Pinxteren, M.E. Numans, P.A. Bonis, J. Lau.
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). En: The Cochrane Library, Issue 2.
[52.]
K.A. Pappa, B.O. Williams, J.E. Payne, K.S. Buaron, K.L. Mussari, A.A. Ciociola.
A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn.
Aliment Pharmacol Ther, 13 (1999), pp. 67-73
[53.]
K.A. Pappa, K. Buaron, J.E. Payne, M.A. Sirgo, E.E. Giefer.
An evaluation of increasing doses of ranitidine for treatment of heartburn.
Aliment Pharmacol Ther, 13 (1999), pp. 475-481
[54.]
K.A. Pappa, W.M. Gooch, K. Buaron, J.E. Payne, E.E. Giefer, M.A. Sirgo, et al.
Low-dose ranitidine for the relief of heartburn.
Aliment Pharmacol Ther, 13 (1999), pp. 459-465
[55.]
B. Hallerback, H. Glise, B. Johansson, A.R. Rosseland, S. Hulten, L. Carling, et al.
Gastro-oesophageal reflux symptoms -Clinical findings and effect of ranitidine treatment.
Eur J Surg, 583 (1998), pp. 6-13
[56.]
N. Chiba, C.J. De Gara, J.M. Wilkinson, R.H. Hunt.
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
Gastroenterology, 112 (1997), pp. 1.798-1.810
[57.]
P.J. Kahrilas, M.B. Fennerty, B. Joelsson.
High -versus standarddose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.
Am J Gastroenterol, 94 (1999), pp. 92-97
[58.]
J.E. Richter, T.O. Kovacs, P.A. Greski-Rose, B. Huang, R. Fisher.
Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Aliment Pharmacol Ther, 13 (1999), pp. 795-804
[59.]
J.E. Richter, D. Peura, S.B. Benjamin, B. Joelsson, J. Whipple.
Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Arch Intern Med, 160 (2000), pp. 1.810-1.816
[60.]
T. Lind, T. Havelund, L. Lundell, H. Glise, K. Lauritsen, S.A. Pedersen, et al.
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial.
Aliment Pharmacol Ther, 13 (1999), pp. 907-914
[61.]
N.J. Talley, K. Lauritsen, H. Tunturi-Hihnalas, T. Lind, B. Moum, C. Bang, et al.
Esomeprazole 20 mg maintains symptoms control in endoscopy-negative gastroesophageal reflux disease: a controlled trial of “on-demand” therapy for 6 months.
Aliment Pharmacol Ther, 15 (2001), pp. 347-354
[62.]
K.D. Bardhan, S. Muller-Lissner, M.A. Bigard, G.B. Porro, J. Ponce, J. Hosie, et al.
Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omprazole or ranitidine.
BMJ, 318 (1999), pp. 502-507
[63.]
N.O. Stalhammar, J. Carlsson, R. Peacock, S. Muller-Lissner, M.A. Bigard, G.B. Porro, et al.
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastrooesophageal reflux disease.
Pharmaeconomics, 16 (1999), pp. 483-497
[64.]
L.B. Gerson, A.S. Robbins, A. Garber, J. Hornberger, G. Triadafilopoulos.
A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Am J Gastroenterol, 95 (2000), pp. 395-407
[65.]
N.J. Talley, T.l. Venables, J.R.B. Green, D. Armstrong, K. O'Kane, M. Giaffer, et al.
Esomeprazole 40 mg and 20 mg is effectivein long-term management of endoscopy negative GORD. A placebo-controlled trial of “on-demand” therapy.
Gastroenterology, 118 (2000), pp. A658
[66.]
T.L. Venables, R.D. Newland, A.C. Patel, J. Hole, C. Wilcock, M.L. Turbitt.
Omeprazole 10 mg once daily, omeprazole 20 mg once daily or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms gastroesophageal reflux in general public.
Scand J Gastroenterol, 32 (1997), pp. 965-973
[67.]
T. Lind, T. Havelund, R. Carlsson, O. Anker-Hansen, H. Glise, H. Hernqvist, et al.
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining response.
Scand J Gastroenterol, 32 (1997), pp. 974-979
[68.]
R. Carlsson, J. Dent, R. Watts, S. Riley, R. Sheikh, J. Hatlebakk, et al.
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 119-124
[69.]
R. Jones, S.L. Crouch.
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Aliment Pharmacol Ther, 13 (1999), pp. 413-419
[70.]
J.E. Richter, W. Bochenek.
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Am J Gastroenterol, 95 (2000), pp. 3.071-3.080
[71.]
J.G. Hatlebakk, A. Hyggen, P.H. Madsen, P.O. Walle, T. Schulz, P. Mowinckel, et al.
Heartburn treatment in primary care: randomised, double blind study for 8 weeks.
BMJ, 319 (1999), pp. 550-553
[72.]
D.L. Earnest, E. Dorsch, J. Jones, D.E. Jennings, P.A. Greski Rose.
A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Am J Gastroenterol, 93 (1998), pp. 238-243
[73.]
C.P. Dekkers, J.A. Beker, B. Thjodleifsson, A. Gabryelewicz, N.E. Bell, T.J. Humphries.
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oeso-phageal reflux disease. The European Rabeprazole Study Group.
Aliment Pharmacol Ther, 13 (1999), pp. 49-57
[74.]
A. Vcev, D. Stimac, A. Vceva, B. Takac, A. Ivandic, D. Pezerovic, et al.
Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
Acta Med Croatica, 53 (1999), pp. 79-82
[75.]
A.S. Mee, J.L. Rowley.
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Aliment Pharmacol Ther, 10 (1996), pp. 757-763
[76.]
C.J. Mulder, W. Dekker, M. Gerretsen.
Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II III and IVa (a Dutch multicentre trial). Dutch Study Group.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 1.101-1.106
[77.]
P. Kahrilas, G. Falk, D.A. Johnson, C. Schmitt, D.W. Collins, J. Whipple, et al.
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oeso-phagitis patients: a randomized controlled trial.
Aliment Pharmacol Ther, 14 (2000), pp. 1.249-1.258
[78.]
J.E. Richter, P.J. Kahrilas, J. Johanson, P. Maton, J.R. Breiter, C. Hwang, et al.
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Am J Gastroenterol, 96 (2001), pp. 656-665
[79.]
R. Fass, U. Murthy, C.W. Hayden, I.B. Malagon, G. Pulliam, C. Wendel, et al.
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.
Aliment Pharmacol Ther, 14 (2000), pp. 1.595-1.603
[80.]
B. Thjodleifsson, J.A. Beker, C. Dekkers, T. Bjaaland, V. Finnegan, T.J. Humphries.
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Dig Dis Sci, 45 (2000), pp. 845-853
[81.]
D.A. Johnson, S.B. Benjamin, N.B. Vakil, J.L. Goldstein, M. Lamet, J. Whipple, et al.
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Am J Gastroenterol, 96 (2001), pp. 27-34
[82.]
E. Vivian, A. Morreale, E. Boyce, K. Lowry, O. Ereso, P. Hlavin.
Efficacy and cost effectiveness of lansoprazole versus omeprazole in maintenance treatment of symptomatic gastroeso-phageal reflux disease.
Am J Managed Care, 5 (1999), pp. 881-886
[83.]
K.D. Bardhan, P. Cherian, A. Vaishnavi, R.B. Jones, M. Thompson, P. Morris, et al.
Erosive oeso-phagitis: Outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.
Gut, 43 (1998), pp. 458-464
[84.]
C.M. Bate, S.N. Booth, J.P. Crowe, R.A. Mountford, P.W. Keeling, B. Hepworth-Jones, et al.
Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.
Gut, 36 (1995), pp. 492-498
[85.]
H.P. Festen, E. Schenk, G. Tan, P. Snel, F. Nelis.
Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short and long-term treatment. The Dutch Reflux Study Group.
Am J Gastroenterol, 94 (1999), pp. 931-936
[86.]
C. Birbara, J. Breiter, C. Perdomo, W. Hahne.
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease.
Europ J Gastroenterol Hepatol, 12 (2000), pp. 889-897
[87.]
A. Caos, M. Moskovitz, Y. Dayal, C. Perdomo, R. Niecestro, J. Barth.
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Am J Gastroenterol, 95 (2000), pp. 3.081-3.088
[88.]
S.J. Sontag, D.G. Kogut, R. Fleischmann, D.R. Campbell, J. Richter, M. Haber.
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Am J Gastroenterol, 91 (1996), pp. 1.758-1.765
[89.]
M. Robinson, F. Lanza, D. Avner, M. Haber.
Effective maintenance treatment of reflux eso-phagitis with low-dose lansoprazole.
Ann Intern Med, 124 (1996), pp. 859-867
[90.]
K. Plein, J. Hotz, H. Wurzer, I. Fumagalli, R. Luhmann, A. Schneider.
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Europ J Gastroenterol Hepatol, 12 (2000), pp. 425-432
[91.]
J. Escourrou, P. Deprez, A. Saggioro, H. Geldof, R. Fischer, C. Maier, et al.
Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis.
Aliment Pharmacol Ther, 13 (1999), pp. 1.481-1.491
[92.]
R.H. Jones, G. Baxter.
Lansoprazole 30 mg daily versus ranitidine 150 mg b. d. in the treatment of acid-related dispepsia in general practice.
Aliment Pharmacol Ther, 11 (1997), pp. 541-546
[93.]
P.N. Maton, R. Orlando, B. Joelsson.
Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial.
Aliment Pharmacol Ther, 13 (1999), pp. 19-26
[94.]
J.E. Richter, D.R. Campbell, P.J. Kahrilas, B. Huang, C. Fludas.
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Arch Intern Med, 160 (2000), pp. 1.803-1.809
[95.]
B. Kaplan-Machlis, G.E. Spiegler, M.W. Zodet, D.A. Revicki.
Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
Arch Fam Med, 9 (2000), pp. 624-630
[96.]
J.H. Van Zyl, H. de K Grundling, C.J. van Rensburg, F.J. Retief, S.J. O'Keefe, I. Theron, et al.
Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 197-202
[97.]
A. Farley, L.D. Wruble, T.J. Humphries.
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Am J Gastroenterol, 95 (2000), pp. 1.894-1.899
[98.]
J.B. Jansen, J.C. Van Oene.
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Aliment Pharmacol Ther, 13 (1999), pp. 1.611-1.620
[99.]
S.J. Sontag, D.G. Kogut, R. Fleischmann, D.R. Campbell, J. Richter, M. Robinson, et al.
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Am J Gastroenterol, 92 (1997), pp. 429-437
[100.]
S. Vigneri, R. Termini, G. Leandro, S. Badalamenti, M. Pantalena, V. Savarino, et al.
A comparison of five maintenance therapies for reflux esophagitis.
N Engl J Med, 333 (1995), pp. 1.106-1.110
[101.]
J.E. Richter, S.M. Sabesin, D.G. Kogut, R.M. Kerr, L.D. Wruble, M.J. Collen.
Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
Am J Gastroenterol, 91 (1996), pp. 1.766-1.772
[102.]
R.W. McCallum, S.M. Fink, G.R. Winnan, J. Avella, C. Callachan.
Metoclopramide in gastroe-sophageal reflux disease: rationale for its use and results of a double-blind trial.
Am J Gastroenterol, 79 (1984), pp. 165-172
[104.]
P.E. Donahue, S. Samelson, L.M. Nyhus, C.T. Bombeck.
The floppy Nissen fundoplication. Effective long-term control of pathologic reflux.
Arch Surg, 120 (1985), pp. 663-668
[105.]
T.R. Demeester, L. Bonavina, M. Albertucci.
Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients.
Ann Surg, 204 (1986), pp. 9-20
[106.]
L.F. Martinez de Haro, A. Ortiz, P. Parrilla, J.A. Garcia Marcilla, J.L. Aguayo, G. Morales.
Long-term results of Nissen fundoplication in reflux esophagitis without strictures.
Clinical, endoscopic, and pH-metric evaluation Dig Dis Sci, 37 (1992), pp. 523-527
[107.]
L. Grande, V. Toledo-Pimentel, C. Manterola, G. Lacima, E. Ros, J.C. Garcia-Valdecasas, et al.
Value of Nissen fundoplication in patients with gastro-oesophageal reflux judged by long-term symptom control.
Br J Surg, 81 (1994), pp. 548-550
[108.]
M. Juan, J. Ponce, V. Garrigues, R. Lopez, J. Mir, J. Berenguer.
Long-term efficacy of 180° anterior fundoplication for severe gastro-oesophageal reflux disease.
Eur J Gastroenterol Hepatol, 4 (1992), pp. 215-219
[109.]
T. Franzen, J. Bostrom, L. Tibbling Grahn, K. Johansson.
Prospective study of symptoms and gastro-oesophageal reflux 10 years after posterior partial fundoplication.
Br J Surg, 86 (1999), pp. 956-960
[110.]
D.A. Katzka.
Digestive system disorders: gastroesophageal reflux disease.
West J Med, 173 (2000), pp. 48-53
[111.]
G. Nilsson, S. Larsson, F. Johnsson.
Randomized clinical trial of laparoscopic versus open fundoplication: blind evaluation of recovery and discharge period.
Br J Surg, 87 (2000), pp. 873-878
[112.]
T.J. Heikkinen, K. Haukipuro, S. Bringman, S. Ramel, A. Sorasto, A. Hulkko.
Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial.
Surg Endosc, 14 (2000), pp. 1.019-1.023
[113.]
L. Lundell, P. Miettinen, H.E. Myrvold, S.A. Pedersen, K. Thor, M. Lamm, et al.
Long-term management of gastroóesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 879-887
[114.]
L. Lundell, P. Miettinen, H.E. Myrvold, S.A. Pedersen, B. Liedman, J.G. Hatlebakk, et al.
Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.
J Am Coll Surg, 192 (2001), pp. 172-179
[115.]
S.J. Spechler, E. Lee, D. Ahnen, R.K. Goyal, I. Hirano, F. Ramirez, et al.
Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.
JAMA, 285 (2001), pp. 2.331-2.338
[117.]
T.K. Rantanen, J.A. Salo, J.T. Sipponen.
Fatal and life-threatening complications in antireflux surgery: analysis of 5,502 operations.
Br J Surg, 86 (1999), pp. 1.573-1.577
[118.]
R.M. Kroes, M.E. Numans, R.H. Jones, N.J. deWit, T.J.M. Verheij.
GERD in primary care. Comparison and development of European guidelines on gastroesophageal reflux disease.
Eur J Gen Pract, 5 (1999), pp. 88-97
[119.]
K.R. DeVault, D.O. Castell.
Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology.
Arch Intern Med, 155 (1995), pp. 2.165-2.173
[120.]
French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease.
Diagnosis and treatment report of a meeting held in Paris, France on 21-22 January 1999 The jury of the consensus conference.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 129-137
[121.]
A.B. Thomson, N. Chiba, D. Armstrong, G. Tougas, R.H. Hunt.
The second Canadian gastroesophageal reflux disease consensus: moving forward to new concepts.
Can J Gastroenterol, 12 (1998), pp. 551-556
[122.]
I.T. Beck, M.C. Champion, S. Lemire, A.B. Thomson, M. Anvari, D. Armstrong, et al.
The 1996 Canadian outlook on gastroesophageal reflux disease. Consensus Conference. Ottawa, Ontario, June 1996.
Can J Gastroenterol, 11 (1997), pp. 1B-112B
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
